Topic

Vice President, Scientific eTech-Enabled Services, Calyx

Articles

In an earlier article, we reviewed the randomization risks that could arise if an interactive response technology (IRT) system isn’t designed and/or implemented correctly. Here we address the consequences that trial sponsors could face if their IRT system isn’t adequately designed to handle the many and often complex drug allocation and trial supply aspects of their clinical trials.    

Getting IRT Right – Part 2: Study Drug Allocation and Supply Management 

Jennifer Ross, MS, M.Phil.Ed, Director of Biostatistics, Almac Clinical Technologies

Kevin Venner, BS, Group Leader, Biostatisticians, Almac Clinical Technologies.

It is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.

Master Protocols: Implementing Effective Treatment Adaptations in the Randomization

This is the first of two articles on the consequences that could arise if an interactive response technology (IRT) system isn’t designed and/or implemented correctly and how a trial could quickly go off track based on risks related to randomization, drug allocation, and trial supply.

Getting IRT Right – Part 1: Randomization

Neta Bendelac, Senior Director of Strategy, 

Identifying areas of burden and steps supply chain operators can take to alleviate them.

Introducing Sustainability into the Clinical Trial Supply Chain

AI can also help reduce waste from 70% to 25%.

Shortening Clinical Drug Supply Timelines Using AI

Panel at SCOPE discusses the possibilities of research in a post-COVID world.






Global Health Crisis Provides Learning Opportunities Moving Forward 

Loftware VP - Lifesciences Product Management

Concept of flexibility acting as driving force behind industry’s swift response to COVID-19.

Clinical Trials Supply Chain: How to Respond to Recent Transformations 

VP Clinical Trials Global Sales, Loftware

How smart packaging can aid clinical trial adherence.

Putting Labeling on the Boardroom Agenda

COVID-19 provides unique opportunity for overhaul of logistics.

Moving into the Future of Clinical Trials

The success of the decentralized model hinges on coordination between stakeholders across the supply chain to ensure that date is secure, medication is delivered on time, and in proper condition.